BACKGROUND
Alcohol misuse is common in the Armed Forces (AF), with prevalence higher than in the general population. To date, initiatives to support alcohol misuse have focused on males, who represent around 90% of the AF. However, woman veterans drink disproportionally more than woman members of the public.
OBJECTIVE
This is a two-arm participant-blinded (single-blinded) confirmatory randomized controlled trial (RCT) aims to assess the efficacy of a brief alcohol intervention (DrinksRation) in reducing weekly self-reported alcohol consumption between baseline and 3 months follow-up (day 84) among woman who have served in the UK AF.
METHODS
In this two-arm, single-blinded RCT, a smartphone app that includes interactive features tailored towards the needs of woman veterans and designed to enhance participants’ motivations to reduce the amount of alcohol they consume is compared with governance guidance on alcohol consumption. The trial will be conducted in woman who have served at least one day of paid service in the UK AF. Recruitment, consent, and data collection will be carried out automatically through the DrinksRation app, or BeAlcoholSmart platform. The primary outcome is change in self-reported weekly alcohol consumption between baseline (day 0) and 3-month follow-up (day 84) measured using the Time-Line Follow back for Alcohol Consumption. The secondary outcome is the change in Alcohol Use Disorder Identification score, measured at baseline and 3-month follow-up between the control and intervention groups. Process evaluation measures include (1) app use and (2) usability ratings as measured by the mHealth App Usability Questionnaire.
RESULTS
RCT recruitment will begin in August 2023 and last for 5 months. We aim to complete all data collection, including interviews, by January 2024.
CONCLUSIONS
This study will assess whether a smartphone app tailored to the needs woman who have served in the UK AF is efficacious in reducing self-reported alcohol consumption. If successful, the digital technology platform could be used to support other conditions and disorders.
CLINICALTRIAL
This study has prospectively been registered on ClinicalTrials.Gov (trial registration: NCT05970484).